2024, An Eventful Trip for MAPS

The Multidisciplinary Association for Psychedelic Studies (MAPS) reflects on the significant challenges of 2024, particularly following the regulatory rejection of MDMA-assisted therapy for PTSD. While the decision hindered immediate clinical integration, it serves as a call to redouble efforts in rigorous research and public policy engagement. Advancing medical access to psychedelic-assisted therapies requires long-term commitment and resilience. MAPS maintains its focus on establishing legal pathways for therapeutic use, emphasizing the continued importance of public education and grounded advocacy to drive societal change.